Drugs / DANIQUIDONE
DANIQUIDONE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00450502 | Feb 2007 → Apr 2011 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DANIQUIDONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL114283 ↗ |
| Known as | Batracylin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00450502 ↗ |
| Known as | BAY H 2049 | ChEMBL registry synonym — accepted as the source's own label CHEMBL114283 ↗ |
| Known as | Daniquidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL114283 ↗ |
| Known as | NSC320846 | “A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas” NCT00450502 ↗ |
| Action | Inhibit | “TOPO II inhibitor” NCT00450502 ↗ |
| Modality | Small molecule | — CHEMBL114283 ↗ |
| Route | Oral | “oral administration of batracylin” NCT00450502 ↗ |